Fox Run Management L.L.C. Takes Position in Novo Nordisk A/S $NVO

Fox Run Management L.L.C. bought a new position in Novo Nordisk A/S (NYSE:NVO) during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 17,673 shares of the company’s stock, valued at approximately $981,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in NVO. Revolve Wealth Partners LLC boosted its position in shares of Novo Nordisk A/S by 8.7% during the 4th quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock valued at $214,000 after acquiring an additional 200 shares during the last quarter. AQR Capital Management LLC raised its stake in Novo Nordisk A/S by 21.0% during the first quarter. AQR Capital Management LLC now owns 62,099 shares of the company’s stock valued at $4,312,000 after purchasing an additional 10,758 shares in the last quarter. Sivia Capital Partners LLC lifted its position in Novo Nordisk A/S by 18.2% during the second quarter. Sivia Capital Partners LLC now owns 10,320 shares of the company’s stock valued at $712,000 after purchasing an additional 1,587 shares during the last quarter. Focus Partners Advisor Solutions LLC grew its stake in shares of Novo Nordisk A/S by 16.3% in the 2nd quarter. Focus Partners Advisor Solutions LLC now owns 7,318 shares of the company’s stock worth $504,000 after buying an additional 1,024 shares in the last quarter. Finally, Nisa Investment Advisors LLC grew its stake in shares of Novo Nordisk A/S by 33.3% in the 2nd quarter. Nisa Investment Advisors LLC now owns 1,200 shares of the company’s stock worth $83,000 after buying an additional 300 shares in the last quarter. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Stock Down 1.4%

Shares of NVO opened at $37.62 on Friday. The firm has a fifty day moving average price of $52.96 and a 200-day moving average price of $52.93. The company has a current ratio of 0.80, a quick ratio of 0.57 and a debt-to-equity ratio of 0.61. The firm has a market capitalization of $167.97 billion, a P/E ratio of 10.84 and a beta of 0.67. Novo Nordisk A/S has a 12-month low of $37.31 and a 12-month high of $91.90.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Tuesday, February 3rd. The company reported $1.01 earnings per share for the quarter, beating analysts’ consensus estimates of $0.90 by $0.11. The company had revenue of $12.43 billion during the quarter, compared to analyst estimates of $11.97 billion. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. Equities research analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Dividend Announcement

The company also recently declared a dividend, which will be paid on Wednesday, April 8th. Investors of record on Monday, March 30th will be issued a $1.2751 dividend. The ex-dividend date is Monday, March 30th. This represents a dividend yield of 541.0%. Novo Nordisk A/S’s payout ratio is presently 23.63%.

Key Stories Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Positive Phase‑2 China results for a triple‑agonist (UBT251) that produced ~20% body‑weight loss, bolstering Novo’s obesity pipeline and collaboration footprint in Greater China. Novo Nordisk’s China Obesity Drug Cuts Nearly One-Fifth Of Body Weight
• Positive Sentiment: Novo signed a strategic deal with Vivtex to develop next‑generation oral obesity/diabetes medicines (deal valued up to ~$2.1bn), which could extend market reach beyond injectables if the oral delivery works at scale. Novo Nordisk partners with Vivtex in up to $2.1 billion deal for oral obesity drugs
• Neutral Sentiment: Short interest fell meaningfully in February (roughly a 15% drop), reducing one source of selling pressure and lowering the days‑to‑cover — a technical datapoint worth monitoring for volatility changes.
• Negative Sentiment: Multiple analyst downgrades and coverage cuts have pressured the stock, with recent notes and headlines pointing to reduced ratings and target cuts amid pipeline and competitive concerns. Novo Nordisk A/S (NYSE:NVO) Stock Rating Lowered by Kepler Capital Markets
• Negative Sentiment: Shareholder litigation inquiries and class‑action investigations have been announced (Pomerantz, Schall Law Firm), creating legal overhang and potential costs/distraction for management. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/S – NVO NVO Investors Have Opportunity to Join Novo Nordisk A/S Fraud Investigation with the Schall Law Firm
• Negative Sentiment: Pricing pressure and a reported halving of Wegovy prices have heightened margin and competitive concerns, feeding the narrative of a structural challenge in the obesity franchise. Novo Nordisk Cuts Wegovy Prices in Half While Its Stock Sits Near a 52-Week Low

Analysts Set New Price Targets

A number of brokerages have issued reports on NVO. BMO Capital Markets restated a “market perform” rating on shares of Novo Nordisk A/S in a research report on Thursday, February 5th. The Goldman Sachs Group restated a “buy” rating on shares of Novo Nordisk A/S in a report on Thursday, January 22nd. CICC Research assumed coverage on Novo Nordisk A/S in a research report on Friday, January 9th. They issued an “outperform” rating and a $73.50 price target for the company. Nordea Equity Research cut shares of Novo Nordisk A/S to a “hold” rating in a research report on Tuesday. Finally, Morgan Stanley restated an “underweight” rating and issued a $42.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, December 3rd. Six analysts have rated the stock with a Buy rating, sixteen have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $56.07.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.